HLA-identical stem cell transplantation: Is there an optimal CD34 cell dose?

Bone Marrow Transplantation

Volumn 31, Issue 10, 2003, Pages 839-845

  Heimfeld, S ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Allogeneic stem cell transplantation; CD34 cell dose; GVHD; Survival; Unrelated donor

Indexed keywords

CD34 ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; DONOR; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; MONONUCLEAR CELL; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; THROMBOCYTE;

ANTIGENS, CD34; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; STEM CELL TRANSPLANTATION;

EID: 0037945532     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704019     Document Type: Short Survey

References (53)

1. Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. N Engl J Med 1977; 296: 61-66.
2. Wagner JE, Zahurak M, Piantadosi S et al. Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. J Clin Oncol 1992; 10: 779-789.
3. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantation from unrelated donors facilitated by the national marrow donor program. N Engl J Med 1993; 328: 593-602.
4. Walters M, Patience M, Leisenring W et al. Bone marrow transplantation for sickle-cell disease. N Engl J Med 1996; 336: 369-376.
5. Szydlo R, Goldman JM, Klein JP et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15: 1767-1777.
6. Gratwohl A, Passweg J, Baldomero H et al. For the European Group for Blood and Marrow Transplantation (EBMT). Blood and marrow transplantation activity in Europe 1997. Bone Marrow Transplant 1999; 24: 231-245.
7. Thomas ED, Blume KG. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 1999; 5: 341-346.
8. Grigg AP, Szer J, Beresford J et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukemia. Br J Haematol 1999; 107: 409-418.
9. Petersdorf E, Anasetti C, Martin PJ et al. Genomics of unrelated-donor hematopoietic cell transplantation. Curr Opin Immunol 2001; 13: 582-589.
10. Anasetti C, Petersdorf EW, Martin PJ et al. Trends in transplantation of hematopoietic stem cells from unrelated donors. Curr Opin Hematol 2001; 8: 337-341.
11. Saba N, Flaig T. Bone marrow transplantation for non-malignant diseases. J Hematother Stem Cell Res 2002; 11: 377-387.
12. Champlin RE, Schmitz N, Horowitz MM et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
13. Blaise D, Kuents M, Fortanier C et al. Randomized trial of bone marrow vs lenograstim-primed blood cell allogeneic transplantation in patients with early stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537-546.
14. Bensinger W, Martin P, Storer B et al. Prospective, randomized trial of transplantation of marrow vs peripheral blood stem cells from HLA-identical siblings in patients treated for hematologic malignancies. N Engl J Med 2001; 344: 175-181.
15. Niederwiesser D, Pepe M, Storb R et al. Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia. Br J Haemotol 1988; 69: 23-28.
16. Paulin T. Importance of bone marrow cell dose in bone marrow transplantation. Clin Transplant 1992; 6: 48-54.
17. Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemia burden, donor HLA-matching, and marrow cell dose. Blood 1997; 89: 4226-4235.
18. Russell JA, Laratt L, Brown C et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177-1183.
19. Barrett AJ, Ringden O, Zhang MJ et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323-3327.
20. Dominietto A, Raiola AM, Van Lint MT et al. Factors influencing hematologic recovery after allogeneic stem cells transplants (HSCT): graft versus host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001; 112: 219-227.
21. Rocha V, Carmagnat MV, Chevret S et al. Influence of bone marrow graft lymphocyte subsets on outcome after HLA- identical sibling transplants. Exp Hematol 2001; 29: 1347-1352.
22. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, post-transplant morbidity, and the rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
23. Anasetti C, Heimfeld S, Rowley S et al. Higher CD34 cell dose is associated with improved survival after marrow transplantation from unrelated donors. Blood 1999; 94: 561a.
24. Przepiorka D, Smith T, Folloder J et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
25. Ilhan O, Arsian O, Arat M et al. The impact of CD34+ cell dose on engraftment in allogeneic peripheral blood stem cell transplantation. Transfusion Sci 1999; 20: 69-71.
26. Davies SM, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood 2000; 96: 4096-4102.
27. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
28. Morariu-Zamfir R, Rocha V, Devergie A et al. Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukemia. Bone Marrow Transplant 2001; 27: 575-580.
29. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
30. Bittencourt H, Rocha V, Chevret S et al. Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood 2002; 99: 2726-2733.
31. Gluckman E. Current status of umbilical cord blood hematopoietic stem cell transplantation. Exp Hematol 2000; 28: 1197-205.
32. Locatelli F, Rocha V, Chastang C et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93: 3662-3671.
33. Wagner JE, Barker JN, DeFor TE et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611-1618.
34. Urbano-Ispizua A, Rozman C, Pimental P et al. The number of CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
35. Urbano-Ispizua A, Carreras E, Marin P et al. Allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings: detrimental effect of a high number of donor CD34+ cells. Blood 2001; 98: 2352-2357.
36. Keever-Taylor CA, Klein JP, Eastwood D et al. Factors affecting neutrophil and platelet reconstitution after T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose. Bone Marrow Transplant 2001; 27: 791-800.
37. Passweg JR, Meyer-Monard S, Gregor M et al. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant 2002; 30: 267-271.
38. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother 1996; 5: 213-226.
39. Johnsen HE, Knudsen LM. Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the Second Nordic Workshop. J Hematother 1996; 5: 237-245.
40. Chang A, Ma DDF. The influence of flow cytometric gating strategy on the standardization of CD34+ cell quantitation: an Australian multicenter study. J Hematother 1996; 5: 605-616.
41. Gratama JW, Orfao A, Barnett D et al. Flow cytometric enumeration of CD34+ hematopoietic stem and progenitor cells. European Working Group on Clinical Cell Analysis. Cytometry 1998; 34: 128-142.
42. Leuner S, Arland M, Kahl C et al. Enumeration of CD34-positive hematopoietic progenitor cells by flow cytometry: comparison of a volumetric assay and the ISHAGE gating strategy. Bone Marrow Transplant 1998; 22: 699-706.
43. Brando B, Barnett D, Janossy G et al. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry 2000; 42: 327-346.
44. Serke S, Johnsen HE. A European reference protocol for quality assessment and clinical validation of autologous hematopoietic blood progenitor and stem cell grafts. Bone Marrow Transplant 2001; 27: 463-470.
45. Leisenring JYW, Fritschle W, Heimfeld S et al. Enumeration of HPC in mobilized peripheral blood with the sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection. Bone Marrow Transplant 2000; 25: 1157-1164.
46. Graf L, Heimfeld S, Torok-Storb B. Comparison of gene expression in CD34+ cells from bone marrow and GCSF-mobilized peripheral blood by high-density oligonucleotide array analysis. Biol Blood Marrow Transplant 2001; 7: 486-494.
47. Demirer T, Ihlan O, Arat M et al. CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation. J Clin Apher 2001; 16: 67-43.
48. Pocock C, Szydlo R, David J et al. Stem cell transplantation for chronic myeloid leukemia: the role of infused marrow cell dose. Hematology J 2001; 2: 265-271.
49. Castro-Malaspina H, Harris RE, Gajewski J et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2002; 99: 1943-1951.
50. Rocha V, Myriam L, Gluckman E et al. Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European Survey. J Clin Oncol 2002; 20: 4324-4330.
51. Singhal S, Powles R, Treleaven J et al. A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.
52. Waller EK, Rosenthal H, Jones TW et al. Larger numbers of CD4-bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97: 2948-2956.
53. Arpinati M, Green CL, Heimfeld S et al. G-CSF mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.